canertinib dihydrochloride has been researched along with gw 2580 in 1 studies
| Studies (canertinib dihydrochloride) | Trials (canertinib dihydrochloride) | Recent Studies (post-2010) (canertinib dihydrochloride) | Studies (gw 2580) | Trials (gw 2580) | Recent Studies (post-2010) (gw 2580) |
|---|---|---|---|---|---|
| 31 | 13 | 6 | 48 | 0 | 40 |
| Protein | Taxonomy | canertinib dihydrochloride (IC50) | gw 2580 (IC50) |
|---|---|---|---|
| Chain A, BDNF/NT-3 GROWTH FACTORS RECEPTOR | Homo sapiens (human) | 0.038 | |
| Chain A, BDNF/NT-3 GROWTH FACTORS RECEPTOR | Homo sapiens (human) | 0.038 | |
| Chain A, BDNF/NT-3 GROWTH FACTORS RECEPTOR | Homo sapiens (human) | 0.038 | |
| High affinity nerve growth factor receptor | Homo sapiens (human) | 0.88 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.003 | |
| Macrophage colony-stimulating factor 1 receptor | Homo sapiens (human) | 0.1947 | |
| Macrophage colony-stimulating factor 1 receptor | Mus musculus (house mouse) | 0.392 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Russu, WA; Shallal, HM | 1 |
1 other study(ies) available for canertinib dihydrochloride and gw 2580
| Article | Year |
|---|---|
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |